The Impact of COVID-19 on Heart Failure: What Happened to the Patients with Heart Failure Who Could Not Visit Our Clinic Amid the COVID-19 Pandemic?

Cho, Dong‐Hyuk

doi:10.36628/ijhf.2021.0014

Cited by 3 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In March 2020, The World Health Organization (WHO) announced COVID-19 infection as a global pandemic [ 7 ]. The intense forms of COVID-19 may causes severe pneumonia that necessitates supportive cares like mechanical ventilation in hospitals [ 8 , 9 ]. Aberrant activation of the immune system accompanied by higher levels of proinflammatory cytokines and chemokines is frequently reported in the intense forms of COVID-19 infection [ 10 , 11 ], and the development of cytokine release syndrome associates with the worsening of the disease that might promote sepsis and multiorgan dysfunction [ 12 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

The prevalence and contributing risk factors of coronavirus disease 2019 infection in patients with metabolic syndrome

et al. 2023

View full text Add to dashboard Cite

Background Components of metabolic syndrome (MetS) was reported to contribute to severe and worse outcomes of coronavirus disease 2019 (COVID-19). Hereby, we evaluated the association of MetS and its components with susceptibility to COVID-19. Methods Here, 1000 subjects with MetS were recruited that were diagnosed via the International Diabetes Federation (IDF) criterion. Real-time PCR was exerted to detect SARS-CoV-2 in the nasopharyngeal swabs. Results Among the MetS patients, 206 (20.6%) cases were detected to have COVID-19. Smoking (OR = 5.04, 95%CI = 3.53–7.21, P < 0.0001) and CVD (OR = 1.62, 95%CI = 1.09–2.40, P = 0.015) were associated with increased chance of COVID-19 infection in the MetS patients. BMI was significantly higher (P = 0.0001) in MetS cases with COVID-19 than those without COVID-19. Obesity was associated with increased susceptibility to COVID-19 in MetS patients (OR = 2.00, 95%CI = 1.47–2.74, P < 0.0001). Total cholesterol, TG, LDL were significantly higher in the MetS cases with COVID-19 than those without COVID-19. Dyslipidemia was associated with increased chance of COVID-19 (OR = 1.50, 95%CI = 1.10–2.05, P = 0.0104). FBS level was significantly higher in the MetS cases with COVID-19. T2DM was associated with increased risk of COVID-19 in MetS patients (OR = 1.43, 95%CI = 1.01-2.00, P = 0.0384). Hypertension was associated with increased chance of COVID-19 in the MetS patients (OR = 1.44, 95%CI = 1.05–1.98, P = 0.0234). Conclusions MetS and its components, like obesity, diabetes, dyslipidemia, cardiovascular complications were associated with increased chance of COVID-19 infection development and probably with aggravated symptoms in such patients.

show abstract

Section: Introductionmentioning

confidence: 99%

The prevalence and contributing risk factors of coronavirus disease 2019 infection in patients with metabolic syndrome

et al. 2023

View full text Add to dashboard Cite

show abstract

Metabolic syndrome and the risk of COVID-19 infection: A nationwide population-based case-control study

Cho

Choi

Gwon

2021

Nutrition, Metabolism and Cardiovascular Diseases

Self Cite

View full text Add to dashboard Cite

Background and aims: Metabolic syndrome (MetS) is a chronic, low-grade inflammatory disease. This study aimed to investigate the impact of MetS on the risk and severity of COV-ID-19. Methods and results: We investigated a nationwide cohort with COVID-19 including all patients who underwent the test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Korea. The COVID-19 group included 4070 patients with positive SARS-CoV-2 test results, and the age-and sex-matched control group included 27,618 subjects with negative SARS-CoV-2 test results. The endpoints were SARS-CoV-2 positivity and the severity of COVID-19. The prevalence of MetS was 24.7% and 24.5% in the COVID-19 and control groups, respectively. The presence of MetS was not associated with the risk of developing COVID-19. Among the components of MetS, central obesity was associated with a higher risk of COVID-19 infection (adjusted odds ratio [aOR], 1.17; 95% confidence interval [CI], 1.06e1.28, P Z 0.001). The presence of MetS was significantly associated with severe COVID-19 (aOR, 1.25; 95% CI, 0.78e2.00, P Z 0.352). Among the individual components of MetS, prediabetes/diabetes mellitus was associated with a higher risk of severe COVID-19 (aOR, 1.61; 95% CI, 1.21e2.13, P Z 0.001). The risk of severe COVID-19 linearly increased according to the number of metabolic components (P for trend Z 0.005). Conclusion:In this nationwide cohort study, the individuals with MetS had a significant increase in the risk of severe COVID-19 infection. These patients, particularly those with central obesity and insulin resistance, deserve special attention amid the COVID-19 pandemic.

show abstract

Association of Angiotensin Receptor Blockers With the Risk of COVID-19 in Korea

Cho

Choi

Gwon

2022

Cardiometab Syndr J

View full text Add to dashboard Cite

The Impact of COVID-19 on Heart Failure: What Happened to the Patients with Heart Failure Who Could Not Visit Our Clinic Amid the COVID-19 Pandemic?

Cited by 3 publications

References 13 publications

The prevalence and contributing risk factors of coronavirus disease 2019 infection in patients with metabolic syndrome

The prevalence and contributing risk factors of coronavirus disease 2019 infection in patients with metabolic syndrome

Metabolic syndrome and the risk of COVID-19 infection: A nationwide population-based case-control study

Association of Angiotensin Receptor Blockers With the Risk of COVID-19 in Korea

Contact Info

Product

Resources

About